Advertisement
U.S. Markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0797
    +0.0003 (+0.0324%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    0.00 (0.00%)
     
  • GBP/USD

    1.2625
    +0.0002 (+0.0189%)
     
  • USD/JPY

    151.3030
    -0.0690 (-0.0456%)
     
  • BTC-USD

    69,974.05
    -781.64 (-1.10%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma.

  • The approval covers adult patients who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

  • Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc to develop and commercialize cilta-cel in December 2017.

  • Related: FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients.

  • The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies or chimeric antigen receptor T-cell therapies.

  • Legend and J&J will sell the drug in Greater China at 70-30 split in profit, and in all other countries in a 50-50 split in profit.

  • Besides the U.S., Carvykti/Cilta-cel is also being reviewed by health authorities in Japan and Europe.

  • Price Action: LEGN shares are up 8.59% at $42.99 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement